Oncotelic Therapeutics, Inc. (OTLC)

Market Cap	9.25M
Revenue (ttm)	70.00K
Net Income (ttm)	-1.24M
Shares Out	406.27M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,681
Open	0.0230
Previous Close	0.0225
Day's Range	0.0225 - 0.0230
52-Week Range	0.0200 - 0.0500
Beta	-0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Vuong Trieu
• Employees: 22
• Stock Exchange: OTCMKTS
• Ticker Symbol: OTLC